Phase II trial of SurVaxM combined with standard therapy in patients with newly diagnosed glioblastoma.

被引：1
|
作者：
Ahluwalia, Manmeet Singh
Reardon, David A.
Abad, Ajay P.
Curry, William T.
Wong, Eric T.
Belal, Ahmed
Qiu, Jingxin
Mogensen, Kathleen
Schilero, Cathy
Casucci, Danielle
Mechtler, Laszlo
Uhlmann, Erik J.
Ciesielski, Michael J.
Fenstermaker, Robert
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Harvard Med Sch, Boston, MA 02115 USA
[4] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[5] Massachusetts Gen Hosp, Boston, MA 02114 USA
[6] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[7] Roswell Pk Canc Inst, Buffalo, NY USA
[8] Dent Neurol Inst, Buffalo, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2041
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2041
引用
收藏
页数：1
相关论文
共 50 条
  • [21] GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.
    Buxton, Meredith Becker
    Alexander, Brian Michael
    Berry, Donald A.
    Cavenee, Webster K.
    Colman, Howard
    De Groot, John Frederick
    Ellingson, Benjamin M.
    Gordon, Gary B.
    Khasraw, Mustafa
    Lassman, Andrew B.
    Li, Wenbin
    Lim, Michael
    Mellinghoff, Ingo K.
    Perry, James R.
    Sulman, Erik P.
    Tanner, Kirk
    Weller, Michael
    Wen, Patrick Y.
    Yung, W. K. Alfred
    Cloughesy, Timothy Francis
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.
    Lee, Eudocia Quant
    Muzikansky, Alona
    Reardon, David A.
    Dietrich, Jorg
    Nayak, Lakshmi
    Duda, Dan G.
    Chukwueke, Ugonma Nnenna
    Beroukhim, Rameen
    Doherty, Lisa M.
    Kane, Caroline
    LaFrankie, Debra C.
    Fontana, Brittney
    Stefanik, Jennifer
    Ruland, Sandra
    Caruso, Victoria
    Bruno, Jennifer
    Gaffey, Sarah C.
    Wen, Patrick Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Current status of a phase III trial of nimotuzumab (ti-EGF-R) in newly diagnosed glioblastoma.
    Bach, F.
    Westphal, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] PHASE I/II TRIAL OF RADIATION THERAPY, TEMOZOLOMIDE AND PEMBROLIZUMAB FOLLOWED BY TEMOZOLOMIDE AND PEMBROLIZUMAB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Dixit, Karan
    Kumthekar, Priya
    Kruser, Timothy
    Bloch, Orin
    Chandler, James
    Tate, Matthew
    Raizer, Jeffrey
    NEURO-ONCOLOGY, 2016, 18 : 19 - 19
  • [25] Phase II trial of erlotinib with temozolomide and concurrent radiation therapy in patients with newly diagnosed glioblastoma multiforme: Final results
    Peereboom, D. M.
    Brewer, C. J.
    Sub, J. H.
    Stevens, G. H.
    Barnett, G. H.
    Toms, S. A.
    Elson, P.
    Vogelbaum, M. A.
    Weil, R. J.
    NEURO-ONCOLOGY, 2006, 8 (04) : 448 - 448
  • [26] Phase II trial of erlotinib with temozolomide and concurrent radiation therapy in patients with newly-diagnosed glioblastoma multiforme.
    Brewer, CJ
    Suh, JH
    Stevens, GHJ
    Barnett, GH
    Toms, S
    Vogelbaum, MA
    Weil, R
    Peereboom, DM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 130S - 130S
  • [27] Safety of idroxioleic acid in combination with standard of care (temozolomide and/or radiation therapy) in newly diagnosed glioblastoma patients: A phase Ib trial
    Balana, C.
    del Barco Berron, S.
    Stradella, A.
    Villanueva Vazquez, R.
    Cuesta, A.
    Torres, J. V.
    Roma, J.
    Taylor, R.
    Escriba, P. V.
    Llobet, E.
    McNicholl, A. G.
    ANNALS OF ONCOLOGY, 2021, 32 : S518 - S518
  • [28] A TITE-CRM phase I/II study of disulfiram and copper with concurrent radiation therapy and temozolomide for newly diagnosed glioblastoma.
    Huang, Jiayi
    DeWees, Todd
    Campian, Jian Li
    Chheda, Milan G.
    Ansstas, George
    Tsien, Christina
    Zipfel, Gregory J.
    Dunn, Gavin P.
    Ippolito, Jospeh E.
    Cairncross, J. Gregory
    Easaw, Jacob C.
    Rubin, Josh
    Kim, Albert H.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Phase III TRIDENT trial: Radiation and temozolomide plus /- tumor treating fields in newly diagnosed glioblastoma.
    Shi, Wenyin
    Kleinberg, Lawrence
    Jeyapalan, Suriya A.
    Goldlust, Samuel Aaron
    Nagpal, Seema
    Reardon, David A.
    Combs, Stephanie E.
    Roberge, David
    Nishigawa, Ryo
    Glas, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] A Phase 1 Trial of ABT-510 Concurrent With Standard Chemoradiation for Patients With Newly Diagnosed Glioblastoma
    Nabors, Louis B.
    Fiveash, John B.
    Markert, James M.
    Kekan, Manasi S.
    Gillespie, George Y.
    Huang, Zhi
    Johnson, Martin J.
    Meleth, Sreelatha
    Kuo, Huichien
    Gladson, Candece L.
    Fathallah-Shaykh, Hassan M.
    ARCHIVES OF NEUROLOGY, 2010, 67 (03) : 313 - 319
12345